• Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients

  • Nov 22 2024
  • Length: 4 mins
  • Podcast

Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients

Listen for free

View show details

  • Summary

  • In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.


    For summary, click here.


    Packer M, Zile MR, Kramer CM, et al. (2024). “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.” New England Journal of Medicine. DOI: 10.1056/NEJMoa2410027


    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available